Filing Details
- Accession Number:
- 0001209191-11-059940
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-12-07 13:26:42
- Reporting Period:
- 2011-12-05
- Filing Date:
- 2011-12-07
- Accepted Time:
- 2011-12-07 13:26:42
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1279695 | Universal Biosensors Inc | UBI | Surgical & Medical Instruments & Apparatus (3841) | 980424072 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1514822 | Paul Wright | 1 Corporate Avenue Rowville Victoria C3 3178 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2011-12-05 | 28,000 | $22,389.57 | 28,000 | No | 4 | P | Indirect | By Macquarie Super Manager |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | By Macquarie Super Manager |
Reported Derivative Holdings
Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | $1.38 | 2018-02-23 | 2,300,000 | 2,300,000 | Direct |
Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|
2018-02-23 | 2,300,000 | 2,300,000 | Direct |
Footnotes
- The prices reported are stated in Australian dollars.
- The reported securities are held by Macquarie Super Manager for the account of the Reporting Person.
- 1,400,000 options vest in equal traunches over three years subject to continued employment at the time of vesting. 500,000 of the options vested upon the Issuer entering into a material partnership/licensing agreement with Siemens Healthcare Diagnostics, Inc on 9 September 2011. 400,000 options vest upon CE marketing or first regulatory approval in the United States of the final test to which the partnership/licensing arranagement relates, subject to continued employment at the time of vesting.